Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary10/15/2019
PHILADELPHIA , Oct. 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that the Nasdaq Hearings Panel has agreed to the transfer of the Company's shares to the Nasdaq Capital Market effective at the open of business on October 15, 2019 and granted the
Toggle Summary08/07/2019
Plan to enter Phase 2 in Adult Onset Still's Disease and other serious rare and orphan diseases PHILADELPHIA , Aug. 7, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase
Toggle Summary08/06/2019
PHILADELPHIA , Aug. 6, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "the Company") today announced that Michael F. Cola , President and Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 1:20 p.m.
Toggle Summary07/15/2019
Entering Phase 2 clinical trials for the treatment of Lymphatic Malformations which include a number of rare and orphan diseases. PHILADELPHIA , July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with
Toggle Summary01/02/2019
PHILADELPHIA , Jan. 2, 2019 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with
Toggle Summary11/26/2018
PHILADELPHIA , Nov. 26, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc.  (NASDAQ: GNMX) (the Company) announced today that the Aevi Genomic Medicine Management team will host a breakfast with Key Opinion Leader (KOL) Robert Findling, M.D., Leonard and Helen R.
Toggle Summary11/01/2018
PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended September 30 , 2018 and provided an overview of the Company's recent corporate progress.
Toggle Summary10/15/2018
- Top-line data for Parts A and B of ASCEND expected in January 2019 PHILADELPHIA , Oct. 15, 2018 /PRNewswire/ --   Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial.  The ASCEND trial is a
Toggle Summary08/29/2018
PHILADELPHIA , Aug. 29, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 5:05
Toggle Summary08/21/2018
- Initiation of enrollment in Part B of the ASCEND trial - Top-line data for Parts A and B of ASCEND expected in Q4 2018 PHILADELPHIA , Aug. 21, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced the sale of 5.1 million shares of its common stock for